Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
Status:
Completed
Trial end date:
2018-09-10
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, open-label, parallel, phase 2a study is to determine the
tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease
experiencing abdominal pain.